Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: Double E who wrote (965)	5/16/1998 7:28:00 PM
From: Joe	Respond to of 4140

"Ophthalmology" Article. The following was posted on the Yahoo board by DCappillo <<The May issue of Ophthalmology has a good research paper on the use of LTK to treat overcorrections from PRK (p 926). This journal is a peer-reviewed, highly respected journal put out by the American Academy of Ophthalmology. It is not a "throw-away" journal or a trade journal prone to hype. Sunrise Tech was specifically mentioned and the procedure was detailed in the article. I was especially interested to see that it was done only under topical anesthetic drops, that the corneal epithelium was not removed and that the "duration of each treatment with a maximum of 8 spots took approximately two seconds." The bottom line is that they found the procedure effective for up to 2 diopters of overcorrection, and that one year after treatment 2/3 of the eyes were stable with no regression. The rest of the eyes were retreated either with the SNRS laser, or a few were retreated with the Nidek unit. The study was performed in Canada. It included 36 eyes that were treated and followed. They found the procedure "generally safe with few side effects.">> It's nice to see confirmation of what most of us that follow the company closely already know in such a prestigious ophthalmic journal. This application of the Sunrise LTK ensures that it will find it's way into most of the treatment centers here in the US and abroad. For those that don't understand what this is all about - when an excimer laser is used to correct the vision of a myope or near-sighted person, overcorrection can occur wherein the patient becomes hyperoptic or far-sighted. This can be a significant problem for the patient, particularly patients in their 40's and older with limited accommodation. A myope has always been able to see near objects, perhaps read, without glasses. It is just a question of how near the objects have to be. If they are overcorrected, they become hyperopic and older patients will always need glasses to see anything in focus. The patient has gone from needing glasses most of the time to needing glasses all of the time. Result - one very unhappy patient. In addition to making the LTK essential augmentation along side the excimer, I believe that this application will help ensure timely, if not accelerated, approval by the FDA.